Stem cell therapies for myocardial infarction in clinical trials: Bioengineering and biomaterial aspects

Akon Higuchi, Nien Ju Ku, Yeh Chia Tseng, Chih Hsien Pan, Hsing Fen Li, S. Suresh Kumar, Qing Dong Ling, Yung Chang, Abdullah A. Alarfaj, Murugan A. Munusamy, Giovanni Benelli, Kadarkarai Murugan

研究成果: 雜誌貢獻回顧評介論文同行評審

32 引文 斯高帕斯(Scopus)

摘要

Cardiovascular disease remains the leading cause of death and disability in advanced countries. Stem cell transplantation has emerged as a promising therapeutic strategy for acute and chronic ischemic cardiomyopathy. The current status of stem cell therapies for patients with myocardial infarction is discussed from a bioengineering and biomaterial perspective in this review. We describe (a) the current status of clinical trials of human pluripotent stem cells (hPSCs) compared with clinical trials of human adult or fetal stem cells, (b) the gap between fundamental research and application of human stem cells, (c) the use of biomaterials in clinical and pre-clinical studies of stem cells, and finally (d) trends in bioengineering to promote stem cell therapies for patients with myocardial infarction. We explain why the number of clinical trials using hPSCs is so limited compared with clinical trials using human adult and fetal stem cells such as bone marrow-derived stem cells.

原文???core.languages.en_GB???
頁(從 - 到)1167-1179
頁數13
期刊Laboratory Investigation
97
發行號10
DOIs
出版狀態已出版 - 1 10月 2017

指紋

深入研究「Stem cell therapies for myocardial infarction in clinical trials: Bioengineering and biomaterial aspects」主題。共同形成了獨特的指紋。

引用此